Tiedemann Trust’s Travere Therapeutics TVTX Stock Holding History

Tiedemann Trust’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-19,593	Closed	-$415	–	89
2014 Q1	$415	Buy	+19,593	New	+$301K	0.05%	70

Other funds holding TVTX

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tiedemann Trust's TVTX Position: Q2 2014 in Review

Tiedemann Trust sold out of Travere Therapeutics (TVTX) in Q2 2014, closing a stake of 19,593 shares — an estimated $415 sold.

Tiedemann Trust first reported a position in TVTX in Q1 2014 and held it in 1 quarter. The position peaked at $415 in Q1 2014. 59 funds tracked by Wall St. Rank hold TVTX as of Q2 2014.

Tiedemann Trust reported no remaining Travere Therapeutics position as of Q2 2014 after selling out during the quarter.
Tiedemann Trust sold 19,593 Travere Therapeutics shares in Q2 2014, an estimated $415.
Tiedemann Trust first reported a position in Travere Therapeutics in Q1 2014 and held it in 1 quarter.
Tiedemann Trust's Travere Therapeutics position peaked at $415 in Q1 2014.
59 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2014.

Based on Tiedemann Trust's 13F filing for Q2 2014, filed 31 Jul 2014.